References
Masetti M, Muratore E, Gori D, Prete A, Locatelli F (2022) Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis. Ann Hematol 101:2497–2506
Dufort Y, Alvarez G, Castiglioni M, Pagés C, Incoronato A, Simon E, Zuccolo S et al (2020) Treatment of childhood acute myeloid leukemia in Uruguay: results of 2 consecutive protocols over 20 years. J Pediatr Hematol Oncol 42:359–366
Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC et al (2014) Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group Trial AAML0531. J Clin Oncol 32:3021–3032
Hyakuna N, Hashii Y, Ishida H, Umeda K, Takahashi Y, Nagasawa M et al (2019) Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial. Pediatr Blood Cancer 66:1–9
Kelly MJ, Horan JT, Alonzo TA, Eapen M, Gerbing RB, He W et al (2014) Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation. Pediatr Blood Cancer 61:269–275
Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M et al (2012) The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica 97:21–29
Lee JM, Yang EJ, Park KM, Lee YH, Chueh H, Hah JO et al (2021) Treatment outcomes of pediatric acute myeloid leukemia in the Yeungnam region: a multicenter retrospective study of the Study Alliance of Yeungnam Pediatric Hematology-Oncology (SAYPH). Children 8:109. https://doi.org/10.3390/children8020109
Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F et al (2013) Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 122:170–178
Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J et al (2010) Minimal residual disease-directed therapy for childhood acute myeloid leukemia: results of the AML02 multicentre trial. Lancet Oncol 11:543–552
Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M et al (2009) Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese childhood AML cooperative study group. J Clin Oncol 27:4007–4013
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
This article does not contain any studies with human participants performed by any of the authors.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Messori, A., Hyeraci, G. Meta-analysis on allogeneic transplant for treating pediatric patients with acute myeloid leukemia in first remission: reanalysis of primary data. Ann Hematol 102, 1603–1605 (2023). https://doi.org/10.1007/s00277-023-05101-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-023-05101-z